EsoCap reports positive topline results from ACESO Phase II trial investigating ESO-101 in eosinophilic esophagitis ESO-101, EsoCap's lead product candidate, consists of a capsule with a rolled-up, thin mucoadhesive film with the anti-inflammatory corticosteroid, mometasone furoateEsoCap's novel targeted delivery...

Sirius and Aceso Partner to Deliver the Patient Room of the Future San Antonio, TX, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Sirius Computer Solutions, Inc. (Sirius), a leading national IT solutions integrator, and Aceso® Interactive (Aceso), a premier provider of...